Venetoclax for AML: changing the treatment paradigm
Abstract: Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of apoptosis in malignancies, the survival of which depends on dysregulation of this pathway. Preclinical data, using various model systems including cell lines and patient samples, suggested targeting...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2019-12-01
|
| Serie: | Blood Advances |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2473952920317213 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|